Elanco Animal Health Incorporated (NYSE:ELAN) Receives $15.83 Consensus Price Target from Brokerages

Elanco Animal Health Incorporated (NYSE:ELAN) has earned an average recommendation of “Hold” from the seven research firms that are covering the company, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $15.17.

Several research analysts recently weighed in on ELAN shares. Leerink Partners started coverage on shares of Elanco Animal Health in a research note on Monday, December 2nd. They issued a “market perform” rating and a $14.00 target price for the company. Piper Sandler cut their target price on shares of Elanco Animal Health from $16.00 to $12.00 and set a “neutral” rating for the company in a research note on Thursday. Morgan Stanley cut their target price on shares of Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 26th. UBS Group cut their target price on shares of Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating for the company in a research note on Wednesday, February 26th. Finally, Barclays dropped their price objective on shares of Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating for the company in a research note on Wednesday, February 26th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. DDD Partners LLC purchased a new stake in shares of Elanco Animal Health during the 4th quarter worth about $5,974,000. Geode Capital Management LLC grew its holdings in shares of Elanco Animal Health by 0.8% during the 3rd quarter. Geode Capital Management LLC now owns 7,868,675 shares of the company’s stock worth $115,623,000 after purchasing an additional 65,303 shares during the period. Atom Investors LP grew its holdings in shares of Elanco Animal Health by 310.3% during the 3rd quarter. Atom Investors LP now owns 345,855 shares of the company’s stock worth $5,081,000 after purchasing an additional 261,559 shares during the period. Harbor Capital Advisors Inc. grew its holdings in shares of Elanco Animal Health by 24.0% during the 4th quarter. Harbor Capital Advisors Inc. now owns 1,084,629 shares of the company’s stock worth $13,135,000 after purchasing an additional 209,734 shares during the period. Finally, Wellington Management Group LLP grew its holdings in shares of Elanco Animal Health by 19.2% during the 3rd quarter. Wellington Management Group LLP now owns 4,007,805 shares of the company’s stock worth $58,875,000 after purchasing an additional 646,522 shares during the period. Institutional investors and hedge funds own 97.48% of the company’s stock.

Elanco Animal Health Trading Up 2.7 %

NYSE:ELAN opened at $11.12 on Friday. The company has a market capitalization of $5.50 billion, a PE ratio of 27.80, a price-to-earnings-growth ratio of 2.50 and a beta of 1.44. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66. Elanco Animal Health has a 52-week low of $10.20 and a 52-week high of $18.80. The stock has a fifty day simple moving average of $11.64 and a 200-day simple moving average of $12.94.

Elanco Animal Health (NYSE:ELAN) last announced its earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.15 by ($0.01). Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The firm had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.01 billion. During the same period in the previous year, the firm posted $0.08 EPS. The company’s revenue for the quarter was down 1.4% compared to the same quarter last year. On average, equities research analysts expect that Elanco Animal Health will post 0.91 earnings per share for the current fiscal year.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.